Discovery of therapeutic target in iMCD published in Blood Advances

09/02/2021 New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease. The international study was led by researchers at Penn Medicine and the Castleman Disease Collaborative Network (CDCN).

Download PDF of Article

Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left